Amdocs (DOX) is in focus after a mixed earnings update, lowered full year profit guidance, and a new quarterly outlook that together highlight margin pressure despite ongoing revenue growth and recent capital returns.

Amdocs' share price has climbed over the past month, with a 30 day share price return of 12.87%. However, this comes after a year to date share price decline of 26.91% and a 1 year total shareholder return decline of 29.96%. This suggests recent momentum is improving from a weak longer term performance as investors reassess the stock after the revised guidance, dividend affirmation and ongoing buybacks.

If Amdocs’ recent moves have you rethinking where the next opportunity might come from, it could be a good moment to check out 56 AI infrastructure stocks as a fresh source of ideas.

Amdocs still looks like a solid, cash returning software business, even as earnings pressure and softer demand weigh on sentiment. After the recent share price rebound, the real question is whether that quality is already fully priced in.

Most Popular Narrative: 28.6% Undervalued

Based on the most followed narrative, Amdocs' fair value of $82.03 sits well above the last close at $58.59. This points to a sizable valuation gap according to HarishPK.

Financially, the company is characterized by strong recurring revenue streams, highlighted by a high renewal rate for managed services, which account for approximately 65% of total revenue, and a substantial 12 month backlog of $4.28 billion. This stability allows the company to pursue a disciplined capital allocation strategy, featuring consistent dividend growth and significant share repurchases.

Curious what sits behind that $82.03 fair value for Amdocs? The narrative leans on recurring cash flows, margin assumptions and a detailed probability model. The full story joins those pieces together.

Result: Fair Value of $82.03 (UNDERVALUED)

However, the Amdocs narrative could be tested if telecom customers delay IT spending or if AI related disruption pressures its software margins more than expected.

Next Steps

With Amdocs, there are clear reasons for both caution and optimism, so it makes sense to move quickly and weigh the evidence yourself using the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Amdocs?

If Amdocs has sharpened your focus, do not stop there. Use a few focused stock lists to spot fresh opportunities before they move out of reach.

• Target potential bargains by scanning companies that currently look mispriced using the 51 high quality undervalued stocks.
• Strengthen your core holdings by reviewing businesses highlighted in the solid balance sheet and fundamentals stocks screener (48 results).
• Get ahead of the crowd by reviewing the screener containing 21 high quality undiscovered gems before they become widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.